In this article we provide an in-depth analysis of the Bank of England’s decision to reduce the Official Bank Rate by 0.25%. 

Why have obesity drugs captivated both the medical community and investors’ attention over the last two years?

Here we discuss the Magnificent 7, why they have performed so well, and why we don’t own all these stocks at such high concentration in CCLA equity portfolios.

Our third benchmark on corporate mental health shows just over one in four (24) of the UK’s largest listed employers have improved their tier performance on workplace mental health in the past year – to the implied benefit of a combined one million employees.

CCLA reacts to findings by Broadstone independent charity consultancy firm. 

CCLA leads group of investors, including NEST and Storebrand, in writing to Amazon over concerns over Amazon’s alleged response to the organising of workers at its Coventry fulfilment centre in the UK. 

CCLA co-files shareholder resolution calling for Amazon to appoint a reputable third-party to produce a gap analysis of their practice vs their labour standards policy.

Here we discuss why we support mandatory scope 3 disclosure, why it matters and how companies are progressing. 

CCLA's response to the UK government's Call for Evidence in October 2023, on ‘Scope 3 Emissions in the UK Reporting Landscape’. 

In sustainable investment circles it has been hard to escape the news that the world's top five money managers are quitting Climate Action 100+. What does this mean for investors and the industry?